Save

Safety and Efficacy Study of Epcoritamab in Subjects With Relapsed/Refractory Chronic Lymphocytic Leukemia and Richter's Syndrome

PHASE1PHASE2RECRUITING

The study is a global, multi-center safety and efficacy trial of epcoritamab, an antibody also known as EPKINLY™ and GEN3013 (DuoBody®-CD3xCD20). Epcoritamab will either be studied as: * Monotherapy, or * Combination therapy: * epcoritamab + venetoclax * epcoritamab + lenalidomide * epcoritamab + R-CHOP (i. e.

, rituximab, cyclophosphamide, doxorubicin hydrochloride, vincristine (Oncovin®) and prednisone). The study includes patients with relapsed/refractory chronic lymphocytic leukemia (R/R CLL)/small lymphocytic lymphoma (SLL) and patients with Richter's Syndrome (RS). Study participants with R/R CLL/SLL are treated either with epcoritamab as monotherapy or epcoritamab + venetoclax.

Study participants with RS are treated either with epcoritamab as monotherapy or epcoritamab + lenalidomide or epcoritamab + R-CHOP. The trial consists of two parts, a dose-escalation phase (phase Ib) and an expansion phase (phase II). Patients with RS are only included in the expansion phase.

Epcoritamab will be injected subcutaneously (under the skin). Standard-of-care and combination treatments (venetoclax, lenalidomide, and R-CHOP) will be given either orally (by mouth) or intravenously (in a vein). Study details include: * Study duration will be up to 5 years.

* The treatment duration for each participant will be between 18 months (1. 5 years) and 24 months (2 years), depending upon the treatment arm assigned. * The visit frequency will be either weekly, every other week, or monthly, depending upon the part of the study.

All participants will receive active drug; no one will be given placebo.

Simpliy with AI

Study details:

The purpose of the dose-escalation phase of the trial is to determine the recommended phase 2 dose (RP2D) and the maximum tolerated dose (MTD; if reached) as well as establish the safety profile of epcoritamab monotherapy and epcoritamab + venetoclax in participants with R/R CLL. The purpose of the expansion phase is to assess and evaluate the preliminary efficacy, safety and tolerability profiles of epcoritamab monotherapy and epcoritamab + venetoclax at the RP2D for patients with R/R CLL/SLL. Along with this, epcoritamab monotherapy, epcoritamab + lenalidomide and epcoritamab + R-CHOP will be evaluated in patients with RS to assess their efficacy, safety and tolerability profiles.

Simplify with AI

Eligibility criteria

Researchers look for people who fit a certain description, called eligibility criteria. See if you qualify.

Inclusion criteria

Eastern Cooperative Oncology Group (ECOG) performance status score of 0, 1 or 2.

Evidence of CD20 positivity in a sample representative of the disease at Screening.

Acceptable hematology parameters and organ function based on baseline bloodwork.

For R/R CLL arms - Must have active CLL/SLL disease requiring treatment per iwCLL 2018 criteria.

For R/R CLL arms - Received at least 2 prior lines of systemic anti-neoplastic therapy including a Bruton's tyrosine kinase (BTK) inhibitor.

For all RS arms - Have tumor biopsy-proven CD20+ Diffuse large B-cell Lymphoma (DLBCL) and a clinical history of CLL/SLL.

For all RS arms - Must have measurable disease by fluorodeoxyglucose-positron emission tomography (FDG-PET) and computed tomography (CT) or magnetic resonance imaging (MRI) scan.

For all RS arms - Must provide mandatory formalin-fixed, paraffin-embedded (FFPE) tumor biopsy sample.

Life expectancy >3 months on standard of care (SOC).

For RS - monotherapy arm: Deemed as ineligible for chemoimmunotherapy at investigator's discretion or participant who refuses to receive intensive chemotherapy.

For RS - lenalidomide combination therapy arm: Deemed as ineligible for chemoimmunotherapy at the investigator's discretion, or participant who refuses to receive intensive chemotherapy. Eligible for treatment with lenalidomide. Must be willing to use contraception and adhere to the Lenalidomide Pregnancy Risk Minimization Plan.

For RS - R-CHOP combination Therapy Arm - Eligible for treatment with R-CHOP.

For R/R CLL - venetoclax combination Therapy arm - after receiving at least 1 prior line of systemic antineoplastic therapy.

Exclusion criteria

Received prior treatment with a CD3×CD20 bispecific antibody.

Received any prior allogeneic hematopoietic stem cell transplantation (HSCT) or solid organ transplantation.

Received (CAR) T-cell therapy within 100 days or an investigational drug within 4 weeks, prior to first dose of epcoritamab.

Autoimmune disease or other diseases that require permanent or high-dose immunosuppressive therapy.

Received vaccination with live vaccines within 28 days.

Clinically significant cardiac disease.

Known current malignancy other than inclusion diagnosis.

Has had major surgery within 4 weeks.

Active hepatitis B virus or active hepatitis C.

Known history of HIV.

For R/R CLL arms - Any history of RS or evidence indicating a potential Richter's transformation.

Received venetoclax within 24 months prior to beginning venetoclax ramp-up for this trial and progressed on treatment.

For all RS arms - Diagnosis of Richter's syndrome not of the DLBCL subtype such as Hodgkin's lymphoma, prolymphocytic leukemia.

RS - Lenalidomide Combination Therapy and RS Monotherapy Arms - received more than 2 prior lines of therapy for RS.

Simplify with AI

Eligibility

Age eligible for study : 18 and older

Healthy volunteers accepted : No

Gender eligible for study: All

Things to know

Study dates

Study start: 2020-11-25

Primary completion: 2029-06-01

Study completion finish: 2029-08-01

Study type

TREATMENT

Phase

PHASE1

PHASE2

Trial ID

NCT04623541

Intervention or treatment

BIOLOGICAL: Epcoritamab

DRUG: rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone

DRUG: Venetoclax

BIOLOGICAL: Epcoritamab

DRUG: Lenalidomide

Conditions

• Small Lymphocytic Lymphoma
• Richter's Syndrome
• Relapsed/Refractory Chronic Lymphocytic Leukemia

Image related to Small Lymphocytic Lymphoma

Condition: Small Lymphocytic Lymphoma, Richter's Syndrome and more
BIOLOGICAL: Epcoritamab and other drugs
Melbourne, Victoria, Australia and more
Sponsor: Genmab

You may be eligible to participate in this trial based on your search. Check eligibility by answering some questions.

Are you running this trial? If you're a clinic or sponsor, you can claim this study. Claim or learn more.

Find a site

Closest Location:

Peter MacCallum Cancer Centre

Research sites nearby

Select from list below to view details:

Peter MacCallum Cancer Centre
Melbourne, Victoria, Australia
Alfred Health
Melbourne, Victoria, Australia
St. George Hospital
Kogarah, New South Wales, Australia
Barwon Health
Geelong, Victoria, Australia

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Participant Group/Arm	Intervention/Treatment
EXPERIMENTAL: Epcoritamab in R/R CLL/SLL In both study phases. Participants in the expansion phase will be treated at the RP2D defined in the dose-escalation phase.	BIOLOGICAL: Epcoritamab Epcoritamab will be administered subcutaneously in cycles of 28 days (except Cycle 1 for high-dose cohorts = 35 days).
EXPERIMENTAL: Epcoritamab in RS Only in expansion phase.	BIOLOGICAL: Epcoritamab Epcoritamab will be administered subcutaneously in cycles of 28 days.
EXPERIMENTAL: Epcoritamab + Venetoclax in R/R CLL/SLL In both study phases. Participants in the expansion phase will be treated at the RP2D defined in the dose-escalation phase.	BIOLOGICAL: Epcoritamab Epcoritamab will be administered subcutaneously in cycles of 28 days (except Cycle 1 for high-dose cohorts = 35 days).
EXPERIMENTAL: Epcoritamab + Lenalidomide in RS Only in expansion phase.	BIOLOGICAL: Epcoritamab Epcoritamab will be administered subcutaneously in cycles of 28 days.
EXPERIMENTAL: Epcoritamab + R-CHOP in RS Only in expansion phase.	BIOLOGICAL: Epcoritamab Epcoritamab will be administered subcutaneously in cycles of 21 days (Cycle 1-6) and 28 days for Cycle 7 and beyond.

What is the study measuring?

Primary outcome

Primary Outcome Measure	Primary Outcome Description	Primary Outcome Time Frame
Dose Escalation Phase (R/R CLL arm): Number of Participants with Dose Limiting Toxicities (DLTs)	DLT events were defined as clinically significant adverse events (AEs) or abnormal laboratory values assessed as unrelated to disease progression, underlying disease, intercurrent illness, or concomitant medications as assessed per Common Terminology Criteria for Adverse Events (NCI-CTCAE) criteria version 5.0.	During the first cycle for low dose cohorts (Cycle length = 28 days) and for high dose cohorts (Cycle length = 35 days)
Dose Escalation Phase: Number of Participants with Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)	Not Specified	From first dose until the end of the safety follow-up period (60 days after last dose)
Dose Escalation Phase: Number of Participants with Cytokine Release Syndrome (CRS), Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS) and Clinical Tumor Lysis Syndrome (CTLS)	CRS and ICANS will be graded based on American Society for Transplantation and Cellular Therapy (ASTCT) criteria. CTLS will be graded according to Cairo-Bishop criteria.	From first dose until the end of the safety follow-up period (60 days after last dose)
Expansion Phase: Overall Response Rate (ORR)	ORR is defined as the percentage of participants who achieve a response of partial response or complete response, prior to initiation of subsequent therapy. R/R CLL participants will be assessed according to International Workshop on Chronic Lymphocytic Leukemia (iwCLL) criteria and the RS participants according to Lugano criteria.	Up to 5 years

Secondary outcome

Secondary Outcome Measure	Secondary Outcome Description	Secondary Outcome Time Frame
Expansion Phase: Number of Participants with TEAEs and SAEs	Not Specified	From first dose until the end of the safety follow-up period (60 days after last dose)
Dose Escalation Phase: ORR	ORR is defined as percentage of participants who achieve a response of partial response or complete response, prior to initiation of subsequent therapy as assessed by iwCLL criteria.	Up to 5 years
Both Phases: Duration of Response (DOR)	DOR is defined among responders, as the time from the initial documentation of response to the date of disease progression or death, whichever occurs earlier.	Up to 5 years
Both Phases: Number of Participants with Complete Remission (CR) / CR with Incomplete Bone Marrow Recovery (CRi)	CR and CRi for R/R CLL participants will be assessed according to iwCLL criteria and CR for the RS participants, according to Lugano criteria.	Up to 5 years
Both Phases: Time to Response (TTR)	TTR is defined among responders, as the time between first dose of epcoritamab and the initial documentation of response.	Up to 5 years
Both Phases: Progression Free Survival (PFS)	PFS is defined as the time from the first dosing date of epcoritamab and the date of disease progression or death, whichever occurs earlier.	Up to 5 years
Both Phases: Overall Survival (OS)	OS is defined as the time from the first dosing date of epcoritamab and the date of death due to any cause.	Up to 5 years
Both Phases: Time to Next Systemic Anti-cancer Therapy (TTNT)	TTNT is defined as the time from the first dosing date of epcoritamab to the first documented administration of subsequent systemic anticancer therapy.	Up to 5 years
Both Phases: Area Under the Concentration-time Curve (AUC) From Time Zero to Last Quantifiable Sample (AUClast) in Epcoritamab	Not Specified	Predose and post dose at multiple timepoints at end of each cycle for low dose and high dose cohorts (Cycle length = 28 days, except Cycle 1 for high dose cohorts = 35 Days)
Both Phases: AUC From Time Zero to Infinity (AUCinf) in Epcoritamab	Not Specified	Predose and post dose at multiple timepoints at end of each cycle for low dose and high dose cohorts (Cycle length = 28 days, except Cycle 1 for high dose cohorts = 35 Days)
Both Phases: Maximum (Peak) Plasma Concentration (Cmax) in Epcoritamab	Not Specified	Predose and post dose at multiple timepoints at end of each cycle for low dose and high dose cohorts (Cycle length = 28 days, except Cycle 1 for high dose cohorts = 35 Days)
Both Phases: Pre-dose (Trough) Concentrations (Cthrough) in Epcoritamab	Not Specified	Predose and post dose at multiple timepoints at end of each cycle for low dose and high dose cohorts (Cycle length = 28 days, except Cycle 1 for high dose cohorts = 35 Days)
Both Phases: Time to Reach Cmax (Tmax) in Epcoritamab	Not Specified	Predose and post dose at multiple timepoints at end of each cycle for low dose and high dose cohorts (Cycle length = 28 days, except Cycle 1 for high dose cohorts = 35 Days)
Both Phases: Elimination Half-life (T1/2) in Epcoritamab	Not Specified	Predose and post dose at multiple timepoints at end of each cycle for low dose and high dose cohorts (Cycle length = 28 days, except Cycle 1 for high dose cohorts = 35 Days)
Both Phases: Total Body Clearance of Drug From Plasma (CL) in Epcoritamab	Not Specified	Predose and post dose at multiple timepoints at end of each cycle for low dose and high dose cohorts (Cycle length = 28 days, except Cycle 1 for high dose cohorts = 35 Days)
Both Phases: Volume of distribution (Vd) in Epcoritamab	Not Specified	Predose and post dose at multiple timepoints at end of each cycle for low dose and high dose cohorts (Cycle length = 28 days, except Cycle 1 for high dose cohorts = 35 Days)
Both Phases: Lymphoid Cells for Immunophenotyping	Evaluation of B cells, T cells and their activation	Up to 5 years
Expansion Phase: Number of Participants with CRS, ICANS and CTLS	CRS and ICANS will be graded based on ASTCT criteria. CTLS will be graded according to Cairo-Bishop criteria.	From first dose until the end of the safety follow-up period (60 days after last dose)
Expansion Phase: Percentage of Participants with Minimal Residual Disease (MRD) Negativity	MRD negativity rate, is defined as the proportion of participants with at least 1 undetectable MRD result according to the specific threshold, prior to initiation of subsequent therapy.	Up to 5 years
Both Phases: Number of Participants with Anti-drug Antibodies (ADA) to Epcoritamab	Not Specified	Up to end of treatment period (Up to 2 years)
Expansion Phase: Number of Participants with Partial Remission (PR)/Nodular Partial Remission (nPR)	nPR is defined as PR with residual nodules or suspicious lymphocytic infiltrates in participants who are in remission. nPR is only calculated for R/R CLL.	Up to 5 years
Both Phases: Duration of MRD Negativity	The time from first achieving MRD negativity after start of treatment to the MRD conversion to positive.	Up to 5 years

Frequently Asked Questions

Please note: some questions and answers are submitted by anonymous patients or using AI, and have not been verified by Clinrol

No questions submitted. Be the first to ask a question!

You may be eligible to participate in this trial based on your search.Apply for study

Are you running this trial? If you're a clinic or sponsor, you can claim this study.Claim this trial

References

Clinical Trials Gov: Safety and Efficacy Study of Epcoritamab in Subjects With Relapsed/Refractory Chronic Lymphocytic Leukemia and Richter's Syndrome